QIBA PET Amyloid Biomarker Committee

09 September 2016 at 9:00 AM CT (GMT-6) Draft Call Summary

In attendance:

Anne Smith, PhD (Co-Chair)Rachid Fahmi, MSc, PhDRathan Subramaniam, MD, PhD, MPHJoe KoudelikSatoshi Minoshima, MD, PhD (Co-Chair)Dawn Matthews, MS, MBANa Sun, PhDJulie LisieckiEric Perlman, MD (Co-Chair)Dawn Matthews, MS, MBANa Sun, PhDJulie Lisiecki

Discussion of the following topics:

- Profile status / timeline
- Conformance
 - o Image analysis workstation
 - Image acquisition device
- NIBIB funded projects
 - Round 5 final reports are due at the end of September
 - Round 6 projects awarded (pending NIBIB COA)
- Poster for RSNA

0

- Design work to be completed off-line, and a draft for review will be prepared for the October 14th call
- RSNA 2016 Annual Meeting
 - The QIBA Working Meeting will be held on Wednesday, November 30th from 2:30 5 pm
 - The Plenary focus at the QIBA Working Meeting will be QIBA's Relevance to Clinical Practice
 - QIBA breakout sessions for nuclear medicine will be held in one room again for those on multiple biomarker committees
- Strategic considerations beyond the Profile

QIBA Round-5 Project Reports due at the end of September

- Analyses to Support Amyloid Imaging Profile Development (Ms. Matthews)
- Biologic and Reader Repeatability of FDG and CT Volumetric Parameters, ACRIN 6678 & MERCK (Dr. Subramaniam)
- Amyloid Brain PET Test-Retest Meta-analysis (Dr. Subramaniam)
- A PET-Metabolic Tumor-Volume-Digital Reference Object, PET-MTV-DRO (Dr. Kinahan)
- A Procedure to Facilitate Greater Standardization of PET Spatial Resolution (Dr. Lodge)
- To see Round-6 approved projects, visit the Steering Committee page on the QIBA wiki

Profile: Next Steps and Milestones:

- Have current version of DRO read by radiologist (UW and Dr. Subramaniam)
- Make requested changes to DRO based on radiologist feedback
- Constrain what DRO tests in optimal way
 - Single Gaussian filter value for smoothing? (Currently set at 6 mm FWHM)
 - o Only one patient morphology will be tested (no time to segment another MRI volume)
 - o Decide whether anatomical regions will be specified
 - \circ $\;$ Decide whether region boundaries will be specified
 - Decide whether test needs to report an overlay of the target and reference regions on the DRO
 - \circ $\,$ MRI will be provided with the DRO series
 - Should multiple realizations include simulation of patient movement?
- Develop limited initial series of DROs and test on IAWs
- Based on feedback, updated DRO series and Profile IAW Conformance Section of Profile

Previous QIBA Posters at RSNA Annual Meetings (posted to wiki): http://qibawiki.rsna.org/index.php/Education

RSNA

September & October Nuclear Medicine WebEx Schedule

Committees (Fridays, 9 am CT):	SPECT Task Forces: (Tuesdays, 2 pm CT)
 Sept 16: SPECT BC Sept 23: Combined NM BCs or Leadership - TBD Sept 30: Tentative hold for PET Amyloid 	Sept 13: Quantitative / Image Analysis – Drs. Miyaoka and Seibyl Sept 20: DRAFT Claim Sept 27: FINALIZE Claim
Oct 07: FDG-PET BC Oct 14: Amyloid BC Oct 21: SPECT BC Oct 28: NM CC @ 9:00 am CT (Friday)	Oct 04:Image Acquisition / Processing for DaTscan – Dr. DewarajaOct 11:Quantitative / Image Analysis – Drs. Miyaoka and SeibylOct 18:Phantoms / DRO Group – Drs. Dickson and Zimmerman